Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles

Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.

Subsidie
€ 1.498.295
2024

Projectdetails

Introduction

Aortic valve diseases are degenerative conditions that develop progressively and insidiously. Once symptoms become evident, life expectancy is significantly reduced. While treatments for these pathologies are widely available, there remains a remarkably high rate of procedural complications.

Impact of Complications

These complications have been shown to have a negative impact on cardiac mortality and the likelihood of rehospitalization for heart failure. This underscores the need for further technological advancements.

Objective

Protego's objective is to determine whether a combination of immunological and biomechanical profiles in patients with aortic valve diseases can effectively predict post-treatment prognosis. My goal is to develop an innovative, validated, and clinically applicable methodology that can identify the best treatment options and predict post-procedural outcomes while minimizing complications.

Methodology

This methodology will serve to determine the timing of treatment for patients with valvular aortic diseases and assess whether the proposed treatment is likely to be beneficial preoperatively, while also minimizing the risk of post-procedural complications. I will achieve this by combining imaging analysis, deep learning algorithms, in silico models, and in vitro tests.

Key Objectives

My approach involves the following key objectives:

  1. Creating a multi-physics digital twin of patients with aortic valve diseases.
  2. Developing a validated, high-fidelity model for treatment with quantification of post-treatment outcomes.
  3. Generating a proof of concept for a clinically applicable predictive model trained using both immunological profiles and biomechanical features of patients.

Conclusion

This innovative approach will provide a deeper understanding of how clinical and biomechanical outcomes correlate with the amplification of inflammation, helping us comprehend the interaction between biomarkers and negative post-treatment prognosis in patients with aortic valve diseases.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.498.295
Totale projectbegroting€ 1.498.295

Tijdlijn

Startdatum1-10-2024
Einddatum30-9-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • POLITECNICO DI MILANOpenvoerder
  • HUMANITAS UNIVERSITY

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC Advanced...

Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis

This project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients.

€ 2.225.906
ERC Advanced...

Real-time Multiscale Imaging of Pathological Calcification - Zooming in on Aortic Valve Calcification

Developing a designer tissue imaging platform to dynamically study extracellular matrix changes in Calcifying Aortic Valve Disease, aiming to uncover mechanisms for future drug therapies.

€ 2.500.000
ERC Starting...

Pushing Boundaries in Pre-clinical Aortopathy Research

This project aims to unravel mechanisms of syndromic thoracic aortic aneurysm and develop effective therapies using patient-derived aorta-on-a-chip models for pre-clinical research.

€ 1.494.848
ERC Advanced...

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

€ 2.500.000
ERC Starting...

Using CARDIac simulations to run in-silicO clinical TRIALS

This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.

€ 1.499.423

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD

The B-specific consortium aims to identify and target specific B-cell subsets to develop personalized therapies for atherosclerosis and improve cardiovascular disease risk assessment and management.

€ 4.006.599
EIC Pathfinder

MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase

The MIRACLE project aims to develop advanced multiomics-based risk prediction models for atherosclerotic cardiovascular disease by integrating genetic data and biomarkers for improved early diagnosis and treatment.

€ 4.000.000
EIC Accelerator

Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular disease

AuriGen's platform aims to reduce chronic cardiac disease deaths and costs in Europe by providing advanced, multi-functional cardiac devices for effective, minimally invasive patient treatment.

€ 2.499.999
EIC Accelerator

A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime

GrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries.

€ 2.500.000
EIC Pathfinder

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

€ 4.475.946